Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GWP42003 for symptomatic treatment of ulcerative colitis
2011-003208-19Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing GWP42003 with Placebo (2 arms). Primary endpoint: Clinical remission by MAYO score at 10 weeks. Started Sep 2011; status: completed.
02
Drugs
cannabidiol
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2011-003208-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003208-19.